乾癬薬の市場規模、シェア、動向分析レポート：クラス別、治療別、投与経路別、流通チャネル別、地域別、セグメント予測、2025年～2030年

乾癬薬市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、乾癬薬の世界市場規模は2030年までに391億1,000万米ドルに達すると推定され、2025年から2030年にかけて10.94%のCAGRで成長する見込みです。

疾患に対する意識の高まり、生物学的製剤に対する償還戦略の増加、高度な診断・技術ツールが乾癬薬の採用を増加させると考えられます。

さらに、乾癬に罹患する患者の裾野の拡大は、成長見通しを促進すると予想されます。乾癬の正確な原因因子は未確定であるが、特定の遺伝的因子や環境因子が発症の引き金となる可能性があります。利用可能な治療のほとんどは、ケラチノサイトの過増殖を止めることで疾患の進行を遅らせることを目的としています。

乾癬は、プラーク型、小斑点型、逆性型、膿疱型および紅皮型の5つの型に分類されます。これらの型は病変部位および病変の特徴によって異なります。紅皮症型乾癬は最もまれであり、プラーク型乾癬は世界中の患者が罹患している最も一般的なタイプです。

乾癬の罹患率は、様々な地域にわたって長年にわたって徐々に上昇しています。この増加は、ライフスタイルの変化だけでなく、遺伝的、環境的な誘因によるものと考えられます。有病率の上昇はまた、疾患制御のための治療に対する反応性の低下や耐性開発にも関連している可能性があります。

乾癬薬市場レポートハイライト

• 腫瘍壊死因子阻害薬が市場を席巻し、2024年には40.88%のシェアを占める。
• 生物学的製剤セグメントは、乾癬に関連する特定の免疫経路に対する選択性が高く、従来の医薬品と比較して疾患管理が大幅に改善されることから、2024年に46.38%のシェアを占め、市場を独占しました。
• 局所投与セグメントは、予測期間中に大きな成長率を記録すると予想されています。
• 非経口薬セグメントは市場を独占し、2024年には41.58%のシェアを占める。
• 病院薬局セグメントは、2024年に乾癬薬業界の主要シェアを占める。
• 北米乾癬薬市場は2024年に世界シェアの38.65%を占め、市場の主導的地位を占めました。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 乾癬薬市場の変数、動向、範囲

• 市場系統の見通し
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• ビジネス環境分析
  • 業界分析- ポーターのファイブフォース分析
  • PESTLE分析
  • パイプライン分析
  • 特許満了分析
  • 価格分析

第4章 乾癬薬市場：クラス別ビジネス分析

• クラス別市場シェア、2025年と2030年
• クラス別セグメントダッシュボード
• 市場規模、予測、動向分析（クラス別、2018～2030年）
• 腫瘍壊死因子阻害剤
• インターロイキン阻害剤
• ビタミンD類似体
• コルチコステロイド
• その他

第5章 乾癬薬市場：治療別ビジネス分析

• 治療別市場シェア、2025年と2030年
• 治療別セグメントダッシュボード
• 市場規模と予測および動向分析（治療別、2018～2030年）
• 外用薬
• 全身的
• 生物学的製剤

第6章 乾癬薬市場：投与経路別ビジネス分析

• 投与経路別市場シェア、2025年と2030年
• 投与経路別セグメントダッシュボード
• 市場規模、予測、動向分析（投与経路別、2018～2030年）
• 経口
• 非経口
• 外用

第7章 乾癬薬市場：流通チャネル別ビジネス分析

• 流通チャネル別市場シェア、2025年と2030年
• 流通チャネル別セグメントダッシュボード
• 市場規模、予測、動向分析（流通チャネル別、2018～2030年）
• 病院薬局
• 小売薬局
• その他の薬局

第8章 乾癬薬市場：地域別推定・動向分析

• 地域別市場シェア分析、2025年と2030年
• 地域別市場ダッシュボード
• 市場規模と予測動向分析、2018～2030年
• 北米
  • 国別、2018年～2030年
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • デンマーク
  • スウェーデン
  • ノルウェー
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東およびアフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第9章 競合情勢

• 参加者概要
• 企業の市況分析
• 企業分類
• 戦略マッピング
• 企業プロファイル/上場企業
  • AbbVie Inc.
  • Amgen Inc.
  • Johnson &Johnson Services, Inc.
  • Novartis AG
  • Eli Lilly and Company
  • AstraZeneca
  • Celgene Corporation
  • UCB SA
  • Merck
  • Boehringer Ingelheim International GmbH

List of Tables

• Table 1 List of secondary sources
• Table 2 List of abbreviations
• Table 3 Global Psoriasis market, by region, 2018 - 2030 (USD Million)
• Table 4 Global Psoriasis market, by class, 2018 - 2030 (USD Million)
• Table 5 Global Psoriasis market, by treatment, 2018 - 2030 (USD Million)
• Table 6 Global Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
• Table 7 Global Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
• Table 8 North America Psoriasis market, by country, 2018 - 2030 (USD Million)
• Table 9 North America Psoriasis market, by class, 2018 - 2030 (USD Million)
• Table 10 North America Psoriasis market, by treatment, 2018 - 2030 (USD Million)
• Table 11 North America Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
• Table 12 North America Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
• Table 13 U.S. Psoriasis market, by class, 2018 - 2030 (USD Million)
• Table 14 U.S. Psoriasis market, by treatment, 2018 - 2030 (USD Million)
• Table 15 U.S. Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
• Table 16 U.S. Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
• Table 17 Canada Psoriasis market, by class, 2018 - 2030 (USD Million)
• Table 18 Canada Psoriasis market, by treatment, 2018 - 2030 (USD Million)
• Table 19 Canada Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
• Table 20 Canada Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
• Table 21 Mexico Psoriasis market, by class, 2018 - 2030 (USD Million)
• Table 22 Mexico Psoriasis market, by treatment, 2018 - 2030 (USD Million)
• Table 23 Mexico Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
• Table 24 Mexico Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
• Table 25 Europe Psoriasis market, by country, 2018 - 2030 (USD Million)
• Table 26 Europe Psoriasis market, by class, 2018 - 2030 (USD Million)
• Table 27 Europe Psoriasis market, by treatment, 2018 - 2030 (USD Million)
• Table 28 Europe Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
• Table 29 Europe Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
• Table 30 UK Psoriasis market, by class, 2018 - 2030 (USD Million)
• Table 31 UK Psoriasis market, by treatment, 2018 - 2030 (USD Million)
• Table 32 UK Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
• Table 33 UK Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
• Table 34 Germany Psoriasis market, by class, 2018 - 2030 (USD Million)
• Table 35 Germany Psoriasis market, by treatment, 2018 - 2030 (USD Million)
• Table 36 Germany Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
• Table 37 Germany Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
• Table 38 France Psoriasis market, by class, 2018 - 2030 (USD Million)
• Table 39 France Psoriasis market, by treatment, 2018 - 2030 (USD Million)
• Table 40 France Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
• Table 41 France Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
• Table 42 Italy Psoriasis market, by class, 2018 - 2030 (USD Million)
• Table 43 Italy Psoriasis market, by treatment, 2018 - 2030 (USD Million)
• Table 44 Italy Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
• Table 45 Italy Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
• Table 46 Spain Psoriasis market, by class, 2018 - 2030 (USD Million)
• Table 47 Spain Psoriasis market, by treatment, 2018 - 2030 (USD Million)
• Table 48 Spain Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
• Table 49 Spain Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
• Table 50 Norway Psoriasis market, by class, 2018 - 2030 (USD Million)
• Table 51 Norway Psoriasis market, by treatment, 2018 - 2030 (USD Million)
• Table 52 Norway Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
• Table 53 Norway Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
• Table 54 Denmark Psoriasis market, by class, 2018 - 2030 (USD Million)
• Table 55 Denmark Psoriasis market, by treatment, 2018 - 2030 (USD Million)
• Table 56 Denmark Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
• Table 57 Denmark Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
• Table 58 Sweden Psoriasis market, by class, 2018 - 2030 (USD Million)
• Table 59 Sweden Psoriasis market, by treatment, 2018 - 2030 (USD Million)
• Table 60 Sweden Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
• Table 61 Sweden Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
• Table 62 Asia Pacific Psoriasis market, by country, 2018 - 2030 (USD Million)
• Table 63 Asia Pacific Psoriasis market, by class, 2018 - 2030 (USD Million)
• Table 64 Asia Pacific Psoriasis market, by treatment, 2018 - 2030 (USD Million)
• Table 65 Asia Pacific Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
• Table 66 Asia Pacific Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
• Table 67 Japan Psoriasis market, by class, 2018 - 2030 (USD Million)
• Table 68 Japan Psoriasis market, by treatment, 2018 - 2030 (USD Million)
• Table 69 Japan Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
• Table 70 Japan Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
• Table 71 China Psoriasis market, by class, 2018 - 2030 (USD Million)
• Table 72 China Psoriasis market, by treatment, 2018 - 2030 (USD Million)
• Table 73 China Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
• Table 74 China Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
• Table 75 India Psoriasis market, by class, 2018 - 2030 (USD Million)
• Table 76 India Psoriasis market, by treatment, 2018 - 2030 (USD Million)
• Table 77 India Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
• Table 78 India Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
• Table 79 Australia Psoriasis market, by class, 2018 - 2030 (USD Million)
• Table 80 Australia Psoriasis market, by treatment, 2018 - 2030 (USD Million)
• Table 81 Australia Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
• Table 82 Australia Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
• Table 83 South Korea Psoriasis market, by class, 2018 - 2030 (USD Million)
• Table 84 South Korea Psoriasis market, by treatment, 2018 - 2030 (USD Million)
• Table 85 South Korea Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
• Table 86 South Korea Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
• Table 87 Thailand Psoriasis market, by class, 2018 - 2030 (USD Million)
• Table 88 Thailand Psoriasis market, by treatment, 2018 - 2030 (USD Million)
• Table 89 Thailand Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
• Table 90 Thailand Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
• Table 91 Latin America Psoriasis market, by country, 2018 - 2030 (USD Million)
• Table 92 Latin America Psoriasis market, by class, 2018 - 2030 (USD Million)
• Table 93 Latin America Psoriasis market, by treatment, 2018 - 2030 (USD Million)
• Table 94 Latin America Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
• Table 95 Latin America Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
• Table 96 Brazil Psoriasis market, by class, 2018 - 2030 (USD Million)
• Table 97 Brazil Psoriasis market, by treatment, 2018 - 2030 (USD Million)
• Table 98 Brazil Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
• Table 99 Brazil Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
• Table 100 Argentina Psoriasis market, by class, 2018 - 2030 (USD Million)
• Table 101 Argentina Psoriasis market, by treatment, 2018 - 2030 (USD Million)
• Table 102 Argentina Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
• Table 103 Argentina Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
• Table 104 Middle East & Africa Psoriasis market, by country, 2018 - 2030 (USD Million)
• Table 105 Middle East & Africa Psoriasis market, by class, 2018 - 2030 (USD Million)
• Table 106 Middle East & Africa Psoriasis market, by treatment, 2018 - 2030 (USD Million)
• Table 107 Middle East & Africa Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
• Table 108 Middle East & Africa Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
• Table 109 South Africa Psoriasis market, by class, 2018 - 2030 (USD Million)
• Table 110 South Africa Psoriasis market, by treatment, 2018 - 2030 (USD Million)
• Table 111 South Africa Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
• Table 112 South Africa Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
• Table 113 Saudi Arabia Psoriasis market, by class, 2018 - 2030 (USD Million)
• Table 114 Saudi Arabia Psoriasis market, by treatment, 2018 - 2030 (USD Million)
• Table 115 Saudi Arabia Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
• Table 116 Saudi Arabia Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
• Table 117 UAE Psoriasis market, by class, 2018 - 2030 (USD Million)
• Table 118 UAE Psoriasis market, by treatment, 2018 - 2030 (USD Million)
• Table 119 UAE Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
• Table 120 UAE Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
• Table 121 Kuwait Psoriasis market, by class, 2018 - 2030 (USD Million)
• Table 122 Kuwait Psoriasis market, by treatment, 2018 - 2030 (USD Million)
• Table 123 Kuwait Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
• Table 124 Kuwait Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Psoriasis market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 Market formulation & validation
• Fig. 8 Market snapshot
• Fig. 9 Therapeutic approach and application outlook (USD Million)
• Fig. 10 Competitive landscape
• Fig. 11 Psoriasis market dynamics
• Fig. 12 Psoriasis market: Porter's five forces analysis
• Fig. 13 Psoriasis market: PESTLE analysis
• Fig. 14 Class market, 2018 - 2030 (USD Million)
• Fig. 15 Tumor Necrosis Inhibitor market, 2018 - 2030 (USD Million)
• Fig. 16 Interleukin Inhibitors market, 2018 - 2030 (USD Million)
• Fig. 17 Vitamin D Analogues market, 2018 - 2030 (USD Million)
• Fig. 18 Corticosteroids market, 2018 - 2030 (USD Million)
• Fig. 19 Others market, 2018 - 2030 (USD Million)
• Fig. 20 Treatment market, 2018 - 2030 (USD Million)
• Fig. 21 Topicals market, 2018 - 2030 (USD Million)
• Fig. 22 Systemic market, 2018 - 2030 (USD Million)
• Fig. 23 Biologics market, 2018 - 2030 (USD Million)
• Fig. 24 Route of Administration market, 2018 - 2030 (USD Million)
• Fig. 25 Oral market, 2018 - 2030 (USD Million)
• Fig. 26 Parenteral market, 2018 - 2030 (USD Million)
• Fig. 27 Topical market, 2018 - 2030 (USD Million)
• Fig. 28 Distribution Channel market, 2018 - 2030 (USD Million)
• Fig. 29 Hospital Pharmacies market, 2018 - 2030 (USD Million)
• Fig. 30 Retail Pharmacies market, 2018 - 2030 (USD Million)
• Fig. 31 Other Pharmacies market, 2018 - 2030 (USD Million)
• Fig. 32 Psoriasis market revenue, by region
• Fig. 33 Regional marketplace: Key takeaways
• Fig. 34 North America Psoriasis market, 2018 - 2030 (USD Million)
• Fig. 35 U.S. country dynamics
• Fig. 36 U.S. Psoriasis market, 2018 - 2030 (USD Million)
• Fig. 37 Canada country dynamics
• Fig. 38 Canada Psoriasis market, 2018 - 2030 (USD Million)
• Fig. 39 Mexico country dynamics
• Fig. 40 Mexico Psoriasis market, 2018 - 2030 (USD Million)
• Fig. 41 Europe Psoriasis market, 2018 - 2030 (USD Million)
• Fig. 42 UK country dynamics
• Fig. 43 UK Psoriasis market, 2018 - 2030 (USD Million)
• Fig. 44 Germany country dynamics
• Fig. 45 Germany Psoriasis market, 2018 - 2030 (USD Million)
• Fig. 46 France country dynamics
• Fig. 47 France Psoriasis market, 2018 - 2030 (USD Million)
• Fig. 48 Italy country dynamics
• Fig. 49 Italy Psoriasis market, 2018 - 2030 (USD Million)
• Fig. 50 Spain country dynamics
• Fig. 51 Spain Psoriasis market, 2018 - 2030 (USD Million)
• Fig. 52 Norway country dynamics
• Fig. 53 Norway Psoriasis market, 2018 - 2030 (USD Million)
• Fig. 54 Sweden country dynamics
• Fig. 55 Sweden Psoriasis market, 2018 - 2030 (USD Million)
• Fig. 56 Denmark country dynamics
• Fig. 57 Denmark Psoriasis market, 2018 - 2030 (USD Million)
• Fig. 58 Asia Pacific Psoriasis market, 2018 - 2030 (USD Million)
• Fig. 59 Japan country dynamics
• Fig. 60 Japan Psoriasis market, 2018 - 2030 (USD Million)
• Fig. 61 China country dynamics
• Fig. 62 China Psoriasis market, 2018 - 2030 (USD Million)
• Fig. 63 India country dynamics
• Fig. 64 India Psoriasis market, 2018 - 2030 (USD Million)
• Fig. 65 Australia country dynamics
• Fig. 66 Australia Psoriasis market, 2018 - 2030 (USD Million)
• Fig. 67 South Korea country dynamics
• Fig. 68 South Korea Psoriasis market, 2018 - 2030 (USD Million)
• Fig. 69 Thailand country dynamics
• Fig. 70 Thailand Psoriasis market, 2018 - 2030 (USD Million)
• Fig. 71 Latin America Psoriasis market, 2018 - 2030 (USD Million)
• Fig. 72 Brazil country dynamics
• Fig. 73 Brazil Psoriasis market, 2018 - 2030 (USD Million)
• Fig. 74 Argentina country dynamics
• Fig. 75 Argentina Psoriasis market, 2018 - 2030 (USD Million)
• Fig. 76 MEA Psoriasis market, 2018 - 2030 (USD Million)
• Fig. 77 South Africa country dynamics
• Fig. 78 South Africa Psoriasis market, 2018 - 2030 (USD Million)
• Fig. 79 Saudi Arabia country dynamics
• Fig. 80 Saudi Arabia Psoriasis market, 2018 - 2030 (USD Million)
• Fig. 81 UAE country dynamics
• Fig. 82 UAE Psoriasis market, 2018 - 2030 (USD Million)
• Fig. 83 Kuwait country dynamics
• Fig. 84 Kuwait Psoriasis market, 2018 - 2030 (USD Million)
• Fig. 85 Company categorization
• Fig. 86 Company market position analysis
• Fig. 87 Strategic framework

Psoriasis Drugs Market Growth & Trends:

The global psoriasis drugs market size is estimated to reach USD 39.11 billion by 2030, registering to grow at a CAGR of 10.94% from 2025 to 2030 according to a new report by Grand View Research, Inc. Rising disease awareness, an increasing number of reimbursement strategies for biologics, and advanced diagnostic and technological tools are likely to increase the adoption of psoriasis therapeutics.

Additionally, the expanding base of patients suffering from psoriasis is anticipated to fuel growth prospects. The exact causative factors for psoriasis are undetermined; however, certain genetic and environmental factors may trigger the disease onset. Most available treatments aim to decelerate disease progression by stopping the hyperproliferation of keratinocyte.

Psoriasis can be classified into five types: plaque, guttate, inverse, pustular, and erythrodermic. The types vary in terms of the site of disease and characterization of lesions. Erythrodermic psoriasis is the rarest and plaque psoriasis is the most prevalent type affecting patients all over the world.

The incidence rate of psoriasis has witnessed a gradual rise over the years across various geographical locations. This increase can be attributed to genetic and environmental triggers as well as lifestyle changes. The rise in prevalence rates could also be associated with declining response or developing resistance to therapies for disease control.

Psoriasis Drugs Market Report Highlights:

• Tumor necrosis factor inhibitors dominated the market and accounted for a share of 40.88% in 2024 as they effectively target the inflammatory pathways crucial to the disease, resulting in major enhancements.
• The biologics segment dominated the market in 2024 with a share of 46.38% as they are highly selective to certain immune pathways in connection to psoriasis and massive improvements in disease management compared to traditional medicines.
• The topical segment is expected to register a significant growth rate over the forecast period.
• The parenteral segment dominated the market, accounting for a 41.58% share in 2024.
• The hospital pharmacies segment accounted for a leading share of the psoriasis drugs industry in 2024.
• North America psoriasis drugs market held a leading market position in 2024, accounting for 38.65% of the global share.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Class
  • 1.2.2. Treatment
  • 1.2.3. Route of Administration
  • 1.2.4. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Psoriasis Drug Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis
  • 3.3.4. Patent Expiry Analysis
  • 3.3.5. Pricing Analysis

Chapter 4. Psoriasis Drug Market: Class Business Analysis

• 4.1. Class Market Share, 2025 & 2030
• 4.2. Class Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Class, 2018 to 2030 (USD Million)
• 4.4. Tumor Necrosos Factor Inhibitors
  • 4.4.1. Tumor Necrosos Factor Inhibitors Market, 2018 - 2030 (USD Million)
• 4.5. Interleukin Inhibitors
  • 4.5.1. Interleukin Inhibitors Market, 2018 - 2030 (USD Million)
• 4.6. Vitamin D Analogues
  • 4.6.1. Vitamin D Analogues Market, 2018 - 2030 (USD Million)
• 4.7. Corticosteroids
  • 4.7.1. Corticosteroids Market, 2018 - 2030 (USD Million)
• 4.8. Others
  • 4.8.1. Other Class Market, 2018 - 2030 (USD Million)

Chapter 5. Psoriasis Drug Market: Treatment Business Analysis

• 5.1. Treatment Market Share, 2025 & 2030
• 5.2. Treatment Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2018 to 2030 (USD Million)
• 5.4. Topicals
  • 5.4.1. Topicals Market, 2018 - 2030 (USD Million)
• 5.5. Systemic
  • 5.5.1. Systemic Market, 2018 - 2030 (USD Million)
• 5.6. Biologics
  • 5.6.1. Biologics Market, 2018 - 2030 (USD Million)

Chapter 6. Psoriasis Drug Market: Route of Administration Business Analysis

• 6.1. Route of Administration Market Share, 2025 & 2030
• 6.2. Route of Administration Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
• 6.4. Oral
  • 6.4.1. Oral Market, 2018 - 2030 (USD Million)
• 6.5. Parental
  • 6.5.1. Parental Market, 2018 - 2030 (USD Million)
• 6.6. Topical
  • 6.6.1. Tropical Market, 2018 - 2030 (USD Million)

Chapter 7. Psoriasis Drug Market: Distribution Channel Business Analysis

• 7.1. Distribution Channel Market Share, 2025 & 2030
• 7.2. Distribution Channel Segment Dashboard
• 7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
• 7.4. Hospital Pharmacies
  • 7.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
• 7.5. Retail Pharmacies
  • 7.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
• 7.6. Other Pharmacies
  • 7.6.1. Others Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 8. Psoriasis Drug Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2025 & 2030
• 8.2. Regional Market Dashboard
• 8.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 8.4. North America
  • 8.4.1. North America Psoriasis Drug Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 8.4.2. U.S.
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Target Disease Prevalence
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. Reimbursement Framework
    • 8.4.2.5. U.S. Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.3. Canada
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Target Disease Prevalence
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Reimbursement Framework
    • 8.4.3.5. U.S. Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.4. Mexico
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Target Disease Prevalence
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. Reimbursement Framework
    • 8.4.4.5. Mexico Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.5. Europe
  • 8.5.1. Europe Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.2. UK
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Target Disease Prevalence
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Reimbursement Framework
    • 8.5.2.5. Uk Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.3. Germany
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Target Disease Prevalence
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Reimbursement Framework
    • 8.5.3.5. Germany Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.4. France
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Target Disease Prevalence
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. Reimbursement Framework
    • 8.5.4.5. France Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.5. Italy
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Target Disease Prevalence
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Reimbursement Framework
    • 8.5.5.5. Italy Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.6. Spain
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Target Disease Prevalence
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. Reimbursement Framework
    • 8.5.6.5. Spain Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.7. Denmark
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Target Disease Prevalence
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. Reimbursement Framework
    • 8.5.7.5. Denmark Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.8. Sweden
    • 8.5.8.1. Key Country Dynamics
    • 8.5.8.2. Target Disease Prevalence
    • 8.5.8.3. Regulatory Framework
    • 8.5.8.4. Reimbursement Framework
    • 8.5.8.5. Sweden Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.9. Norway
    • 8.5.9.1. Key Country Dynamics
    • 8.5.9.2. Target Disease Prevalence
    • 8.5.9.3. Regulatory Framework
    • 8.5.9.4. Reimbursement Framework
    • 8.5.9.5. Norway Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.6. Asia Pacific
  • 8.6.1. Asia Pacific Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.2. Japan
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Target Disease Prevalence
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Reimbursement Framework
    • 8.6.2.5. Japan Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.3. China
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Target Disease Prevalence
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Reimbursement Framework
    • 8.6.3.5. China Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.4. India
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Target Disease Prevalence
    • 8.6.4.3. Regulatory Framework
    • 8.6.4.4. Reimbursement Framework
    • 8.6.4.5. India Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.5. Australia
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Target Disease Prevalence
    • 8.6.5.3. Regulatory Framework
    • 8.6.5.4. Reimbursement Framework
    • 8.6.5.5. Australia Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.6. South Korea
    • 8.6.6.1. Key Country Dynamics
    • 8.6.6.2. Target Disease Prevalence
    • 8.6.6.3. Regulatory Framework
    • 8.6.6.4. Reimbursement Framework
    • 8.6.6.5. South Korea Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.7. Thailand
    • 8.6.7.1. Key Country Dynamics
    • 8.6.7.2. Target Disease Prevalence
    • 8.6.7.3. Regulatory Framework
    • 8.6.7.4. Reimbursement Framework
    • 8.6.7.5. Thailand Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.7. Latin America
  • 8.7.1. Latin America Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7.2. Brazil
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Target Disease Prevalence
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. Reimbursement Framework
    • 8.7.2.5. Japan Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7.3. Argentina
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Target Disease Prevalence
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. Reimbursement Framework
    • 8.7.3.5. China Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.8. Middle East and Africa
  • 8.8.1. Middle East and Africa Psoriasis Drug Market Estimates and Forecasts, 2017 - 2030 (USD Million)
  • 8.8.2. South Africa
    • 8.8.2.1. Key Country Dynamics
    • 8.8.2.2. Target Disease Prevalence
    • 8.8.2.3. Regulatory Framework
    • 8.8.2.4. Reimbursement Framework
    • 8.8.2.5. South Africa Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.3. Saudi Arabia
    • 8.8.3.1. Key Country Dynamics
    • 8.8.3.2. Target Disease Prevalence
    • 8.8.3.3. Regulatory Framework
    • 8.8.3.4. Reimbursement Framework
    • 8.8.3.5. Saudi Arabia Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.4. UAE
    • 8.8.4.1. Key Country Dynamics
    • 8.8.4.2. Target Disease Prevalence
    • 8.8.4.3. Regulatory Framework
    • 8.8.4.4. Reimbursement Framework
    • 8.8.4.5. UAE Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.5. Kuwait
    • 8.8.5.1. Key Country Dynamics
    • 8.8.5.2. Target Disease Prevalence
    • 8.8.5.3. Regulatory Framework
    • 8.8.5.4. Reimbursement Framework
    • 8.8.5.5. Kuwait Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Participant Overview
• 9.2. Company Market Position Analysis
• 9.3. Company Categorization
• 9.4. Strategy Mapping
• 9.5. Company Profiles/Listing
  • 9.5.1. AbbVie Inc.
    • 9.5.1.1. Overview
    • 9.5.1.2. Financial Performance
    • 9.5.1.3. Product Benchmarking
    • 9.5.1.4. Strategic Initiatives
  • 9.5.2. Amgen Inc.
    • 9.5.2.1. Overview
    • 9.5.2.2. Financial Performance
    • 9.5.2.3. Product Benchmarking
    • 9.5.2.4. Strategic Initiatives
  • 9.5.3. Johnson & Johnson Services, Inc.
    • 9.5.3.1. Overview
    • 9.5.3.2. Financial Performance
    • 9.5.3.3. Product Benchmarking
    • 9.5.3.4. Strategic Initiatives
  • 9.5.4. Novartis AG
    • 9.5.4.1. Overview
    • 9.5.4.2. Financial Performance
    • 9.5.4.3. Product Benchmarking
    • 9.5.4.4. Strategic Initiatives
  • 9.5.5. Eli Lilly and Company
    • 9.5.5.1. Overview
    • 9.5.5.2. Financial Performance
    • 9.5.5.3. Product Benchmarking
    • 9.5.5.4. Strategic Initiatives
  • 9.5.6. AstraZeneca
    • 9.5.6.1. Overview
    • 9.5.6.2. Financial Performance
    • 9.5.6.3. Product Benchmarking
    • 9.5.6.4. Strategic Initiatives
  • 9.5.7. Celgene Corporation
    • 9.5.7.1. Overview
    • 9.5.7.2. Financial Performance
    • 9.5.7.3. Product Benchmarking
    • 9.5.7.4. Strategic Initiatives
  • 9.5.8. UCB S.A.
    • 9.5.8.1. Overview
    • 9.5.8.2. Financial Performance
    • 9.5.8.3. Product Benchmarking
    • 9.5.8.4. Strategic Initiatives
  • 9.5.9. Merck
    • 9.5.9.1. Overview
    • 9.5.9.2. Financial Performance
    • 9.5.9.3. Product Benchmarking
    • 9.5.9.4. Strategic Initiatives
  • 9.5.10. Boehringer Ingelheim International GmbH
    • 9.5.10.1. Overview
    • 9.5.10.2. Financial Performance
    • 9.5.10.3. Product Benchmarking
    • 9.5.10.4. Strategic Initiatives